What is Biofrontera?
Biofrontera Inc. is a biopharmaceutical firm dedicated to the commercialization of pharmaceutical products for dermatological conditions in the United States. The company's portfolio includes treatments for actinic keratoses, a precursor to skin cancer, and impetigo, a bacterial skin infection. Key offerings are Ameluz, a prescription drug used in photodynamic therapy for actinic keratosis, and Xepi, a topical treatment for impetigo. Established in 2015 and headquartered in Woburn, Massachusetts, Biofrontera is strategically positioned to address unmet needs in the dermatology market.
How much funding has Biofrontera raised?
Biofrontera has raised a total of $17.5M across 2 funding rounds:
Debt
$6.5M
Private Equity
$11M
Debt (2023): $6.5M with participation from MidCap Business Credit
Private Equity (2025): $11M, investors not publicly disclosed
Key Investors in Biofrontera
MidCap Business Credit
MidCap Business Credit LLC is an independent commercial finance company which provides asset based loans for companies unable to obtain traditional bank financing. Their participation suggests Biofrontera is utilizing debt financing to support its operational growth and strategic initiatives.
What's next for Biofrontera?
The recent major strategic investment signals a pivotal growth phase for Biofrontera. This influx of capital is anticipated to fuel further research and development, expand commercialization efforts for its existing product lines, and potentially explore new therapeutic areas within dermatology. The company's trajectory suggests a focus on scaling operations and solidifying its market presence, leveraging its innovative treatments to capture greater market share.
See full Biofrontera company page
